Unum
UNM
$93.56
-1.71%
Unum Group is a leading provider of group and individual income protection insurance products, including disability, life, long-term care, and employer- and employee-paid group benefits, operating primarily in the United States, the United Kingdom, and Poland. The company is the largest domestic disability insurer, with the majority of premiums generated from employer plans, and it markets its products through brokers, giving it a distinct position as a specialized benefits provider rather than a broad-based multiline carrier. The current investor narrative centers on a sharp earnings recovery in 2026, with Q1 2026 net income of $232 million and EPS of $1.41 rebounding from a weak Q3 2025, alongside an aggressive share repurchase program that has reduced shares outstanding from over 186 million in mid-2024 to roughly 164 million by Q1 2026. Management's execution on buybacks, premium growth, and margin stabilization is the key debate, with recent commentary suggesting that the stock's prior weakness could reverse if these initiatives gain traction.…
UNM
Unum
$93.56
Related headlines
Investment Opinion: Should I buy UNM Today?
The synthesized recommendation is a Hold with a slight bullish tilt. The core thesis is that Unum offers a compelling forward valuation (10.06x forward PE) and strong capital returns, but the extreme earnings volatility and limited analyst upside (average target of $101.85, just 7.0% above the current price) warrant caution. The consensus analyst rating is moderately bullish, with 13 analysts covering the stock and recent actions from Evercore ISI, Jefferies, Wells Fargo, and Barclays maintaining Outperform or Overweight ratings, while Morgan Stanley and B of A Securities are more neutral.
Supporting evidence includes the forward PE of 10.06x, which is well below the trailing PE of 18.11x and the insurance sector average of 12-15x, implying significant expected earnings growth. Revenue grew 9.02% year-over-year in Q1 2026 to $3.355 billion, and net margin recovered to 6.91% from 1.18% in Q3 2025. The company generated $301.2 million in free cash flow in Q1 2026 and repurchased $398.8 million of stock, reducing shares outstanding by 12% since mid-2024. The dividend yield of 2.29% with a 41.46% payout ratio is sustainable and provides income.
The biggest risks that could invalidate the thesis are a renewed earnings collapse (as seen in Q3 2025), a failure to achieve the $12.05 estimated EPS, and valuation compression if the trailing PE reverts to its historical median of 10-12x. The rating would upgrade to Buy if the forward PE remains below 10x and revenue growth accelerates above 10%, or downgrade to Sell if net income fails to exceed $150 million in the next quarter or if the stock breaks below the $85 support level. Relative to its history and peers, UNM appears fairly valued on a trailing basis but undervalued on a forward basis, assuming the earnings recovery continues.
Sign up to view all
UNM 12-Month Price Forecast
The forward-looking view is cautiously optimistic but tempered by significant earnings volatility. The company's ability to sustain the Q1 2026 recovery and achieve the $12.05 EPS estimate is critical; if it does, the stock could reach $110-$122. However, the limited analyst upside and the risk of another earnings miss keep the stance neutral. I would upgrade to bullish if Q2 2026 EPS exceeds $1.40 and revenue growth accelerates above 10%, or downgrade to bearish if net income falls below $150 million in any quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Unum's 12-month outlook, with a consensus price target around $101.85 and implied upside of +8.9% versus the current price.
Average Target
$101.85
0 analysts
Implied Upside
+8.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$88 - $122
Analyst target range
Unum is covered by 13 analysts, with a consensus recommendation that leans bullish based on recent ratings. The average target price is $101.85, which implies an upside of approximately +7.0% from the current price of $95.19. The analyst community appears constructive, with recent actions from firms like Evercore ISI, Jefferies, Wells Fargo, and Barclays all maintaining Outperform or Overweight ratings, while Morgan Stanley and B of A Securities have more neutral stances.
The target price range spans from a low of $88.00 to a high of $122.00, representing a wide spread that signals differing views on the company's prospects. The high target of $122.00 implies a +28.2% upside and likely assumes successful execution on buybacks, premium growth, and margin expansion, while the low target of $88.00 suggests a -7.6% downside and may reflect concerns about competitive pressures or a challenging macro environment. The wide range indicates uncertainty, but the concentration of recent ratings in the Buy/Outperform category suggests that the consensus is moderately bullish, with the average target offering modest upside from current levels.
Bulls vs Bears: UNM Investment Factors
The bull case rests on a sharp earnings recovery, aggressive share buybacks, and a forward PE of 10.06x that suggests deep value if analyst estimates materialize. The bear case highlights extreme earnings volatility, a trailing PE of 18.11x that is above historical norms, and limited analyst upside of just 7%. Currently, the bull evidence appears stronger given the Q1 2026 rebound, the 12% reduction in share count, and the stock's 24.84% one-year gain. The single most important tension is whether the forward EPS estimate of $12.05 is achievable; if it is, the stock is undervalued, but if earnings disappoint again, the premium trailing multiple could compress sharply.
Bullish
- Earnings recovery underway: Q1 2026 net income rebounded to $232 million (EPS $1.41) from a depressed $39.7 million in Q3 2025, with net margin recovering to 6.91% from 1.18%. This sharp sequential improvement suggests the worst of the earnings volatility is behind the company.
- Aggressive buyback shrinks share count: Shares outstanding fell from over 186 million in mid-2024 to 164.1 million by Q1 2026, a reduction of roughly 12%. The company repurchased $398.8 million of stock in Q1 2026 alone, providing a powerful tailwind to EPS even if net income is flat.
- Forward PE implies deep value: The forward PE of 10.06x is well below the trailing PE of 18.11x and the broader insurance sector's typical 12-15x range. This gap implies the market expects significant EPS growth, with analyst estimated EPS averaging $12.05 for the next fiscal year.
- Strong relative momentum: UNM has gained 24.84% over the past year versus the S&P 500's 15.01%, with a 1-month relative strength of +9.57%. The stock is trading near its 52-week high of $96.77, signaling persistent market leadership.
Bearish
- Earnings volatility remains high: Net income has swung from $645.7 million in Q3 2024 to $39.7 million in Q3 2025 and back to $232 million in Q1 2026. This extreme volatility makes forecasting difficult and raises questions about the sustainability of the recovery.
- Trailing PE at a premium to history: The trailing PE of 18.11x is above the historical median of 10-12x and the insurance sector average of 12-15x. If earnings fail to meet the optimistic forward estimates, the stock could re-rate sharply lower.
- Revenue growth is modest: Q1 2026 revenue grew 9.02% year-over-year, but sequential revenue has been flat in the $3.2-$3.4 billion range for several quarters. Without accelerating top-line growth, margin expansion must do all the heavy lifting.
- Analyst upside is limited: The average analyst target of $101.85 implies only 7.0% upside from the current price of $95.19. The low target of $88.00 suggests a potential 7.6% downside, indicating a less favorable risk/reward at current levels.
UNM Technical Analysis
UNM is in a sustained uptrend, with a 1-year price change of +24.84% and a 6-month gain of +31.26%, significantly outpacing the S&P 500's +15.01% and +17.44% over the same periods. At a current price of $95.19, the stock is trading at approximately 94.3% of its 52-week range (low of $69.02, high of $96.77), positioning it near the upper end of its annual range. This proximity to highs signals strong momentum but also raises the risk of overextension, especially given the stock's low beta of 0.264, which suggests it typically moves less than a third as much as the broader market.
Short-term momentum is accelerating, with a 1-month gain of +8.61% and a 3-month gain of +5.79%, both outpacing the S&P 500's -0.96% and +2.00% respectively. The relative strength over 1 month is +9.57%, indicating significant outperformance, and the 1-year relative strength of +9.83% confirms persistent leadership. However, the 3-month change of +5.79% is lower than the 1-month change, suggesting that momentum has picked up recently after a period of consolidation, and the stock's recent price of $95.19 is just below the 52-week high of $96.77, which could act as a near-term resistance level.
Key technical levels include support at the 52-week low of $69.02, with intermediate support likely around the $85-$87 area, and resistance at the 52-week high of $96.77. A breakout above $96.77 would signal a continuation of the uptrend and could attract momentum buyers, while a breakdown below $85 could indicate a trend reversal. The stock's beta of 0.264 implies very low volatility relative to the market, which may appeal to risk-averse investors but also means that position sizing should account for the potential for larger-than-expected moves if the stock re-rates. The maximum drawdown of -12.08% over the past year is relatively modest, reflecting the stock's defensive characteristics.
Beta
0.26
0.26x market volatility
Max Drawdown
-12.1%
Largest decline past year
52-Week Range
$69-$97
Price range past year
Annual Return
+22.8%
Cumulative gain past year
| Period | UNM Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +1.0% |
| 3m | +2.4% | +5.4% |
| 6m | +25.6% | +17.8% |
| 1y | +22.8% | +16.5% |
| ytd | +21.1% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNM Fundamental Analysis
Unum's revenue trajectory is showing steady growth, with Q1 2026 revenue of $3.355 billion representing a 9.02% year-over-year increase from Q1 2025's $3.078 billion. The multi-quarter trend reveals some volatility: Q4 2025 revenue was $3.243 billion, Q3 2025 was $3.358 billion, and Q2 2025 was $3.346 billion, indicating that revenue has been relatively flat in the $3.2-$3.4 billion range over the past year. The Unum US segment is the largest contributor with $2.066 billion in revenue, followed by Colonial Life at $520 million, Closed Block at $435 million, and Unum International at $320 million, with the core US business driving overall growth.
Profitability has been volatile but is recovering. Q1 2026 net income was $232 million with a net margin of 6.91%, up from Q4 2025's $174 million and 5.37% margin, and a significant improvement from Q3 2025's depressed $39.7 million and 1.18% margin. The gross margin in Q1 2026 was 40.27%, compared to 41.62% in Q4 2025 and 21.99% in Q3 2025, showing a return to more normalized levels. The operating margin of 9.02% in Q1 2026 is below the 13.91% seen in Q4 2024, but the trend is positive, and the company's ROE of 6.64% and ROA of 1.11% are modest but typical for the insurance industry.
Unum's balance sheet remains solid, with a debt-to-equity ratio of 0.351, which is conservative for an insurer. The company generated $340.8 million in operating cash flow in Q1 2026 and $301.2 million in free cash flow, supporting its dividend and buyback programs. The dividend yield is 2.29% with a payout ratio of 41.46%, and the company repurchased $398.8 million of stock in Q1 2026, demonstrating strong capital return. The current ratio is not available (0), but the company's cash position of $192.6 million at the end of Q1 2026 is adequate given its stable cash flows.
Quarterly Revenue
$3.4B
2026-03
Revenue YoY Growth
+9.0%
YoY Comparison
Gross Margin
40.3%
Latest Quarter
Free Cash Flow
$538800000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNM Overvalued?
Since Unum is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 18.11x, while the forward PE is 10.06x, implying that the market expects significant earnings growth in the coming year. This large gap between trailing and forward PE suggests that analysts anticipate a substantial increase in EPS, likely driven by continued buybacks and margin recovery, with estimated EPS averaging $12.05 for the next fiscal year.
The stock's PS ratio of 1.02x is low compared to the industry average, but the PE ratio of 18.11x is above the historical average for Unum. The PB ratio of 1.20x is also modest, indicating that the stock is not expensive on a book value basis. Compared to the broader insurance sector, which often trades at a PE of 12-15x, Unum's trailing PE of 18.11x represents a premium, but the forward PE of 10.06x suggests a discount if earnings materialize as expected. The PEG ratio is negative at -0.33, which is not meaningful due to the earnings volatility.
Historically, Unum's PE ratio has ranged from as low as 3.8x in Q3 2022 to as high as 84.5x in Q3 2025, with a median around 10-12x. The current trailing PE of 18.11x is above the historical median, but the forward PE of 10.06x is more in line with historical norms. The PS ratio of 1.02x is near the low end of its historical range, which could indicate a value opportunity if revenue growth continues. The stock's price-to-free-cash-flow ratio of 19.44x is also reasonable, suggesting that the company is generating solid cash flow relative to its market cap.
PE
18.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Unum's financial and operational risks are centered on earnings volatility and revenue concentration. Net income has been highly erratic, swinging from $645.7 million in Q3 2024 to just $39.7 million in Q3 2025 before recovering to $232 million in Q1 2026. This volatility, combined with a modest 9.02% year-over-year revenue growth and a heavy reliance on the Unum US segment ($2.066 billion of $3.355 billion in Q1 2026 revenue), means that any deterioration in the core disability business could disproportionately impact results. Additionally, the company's ROE of 6.64% and ROA of 1.11% are relatively low, limiting the buffer against unexpected claims or investment losses.
Market and competitive risks include valuation compression and sector rotation. The trailing PE of 18.11x is above the insurance sector's typical 12-15x range, leaving the stock vulnerable if earnings fail to meet the optimistic forward estimates. With a beta of 0.264, UNM is less sensitive to broad market moves, but this also means it may underperform in a strong bull market. The low beta, however, does not protect against company-specific issues such as competitive pressures in the disability insurance market or regulatory changes affecting long-term care reserves. Recent news highlights that the stock's prior weakness could reverse only if management executes on buybacks, premium growth, and margin stabilization, underscoring the execution risk.
The worst-case scenario would involve a renewed earnings collapse, perhaps due to a spike in disability claims or a long-term care reserve charge, similar to the Q3 2025 quarter when net income fell to $39.7 million. If the stock were to retest its 52-week low of $69.02, that would represent a decline of approximately 27.5% from the current price of $95.19. The analyst low target of $88.00 implies a more modest 7.6% downside, but a severe earnings miss could push the stock below that level. In a realistic adverse scenario, an investor could lose 15-25% from current levels if the forward EPS estimates are not met and the trailing PE compresses toward the historical median of 10-12x.
FAQ
The most severe risk is earnings volatility, as demonstrated by the swing from $645.7 million net income in Q3 2024 to $39.7 million in Q3 2025. Second, valuation compression risk is high because the trailing PE of 18.11x is above historical norms; a re-rating to 12x would imply a stock price near $63. Third, competitive pressures in the disability insurance market could erode market share and margins. Fourth, macro sensitivity is low due to the 0.264 beta, but a rise in unemployment could increase disability claims and hurt profitability. Finally, regulatory changes affecting long-term care reserves could trigger large charges.
The 12-month forecast has three scenarios: a bull case (25% probability) targeting $110-$122 if EPS reaches $13.39 and buybacks accelerate; a base case (55% probability) targeting $98-$105 if EPS averages $12.05 and revenue grows 8-9%; and a bear case (20% probability) targeting $69-$88 if earnings collapse again or reserves increase. The base case is most likely, assuming the company sustains its Q1 2026 recovery and meets analyst estimates. The key assumption is that net income remains above $200 million per quarter and the forward PE stays near 10x.
On a trailing basis, UNM appears overvalued with a PE of 18.11x, above the insurance sector average of 12-15x and its historical median of 10-12x. However, on a forward basis, the PE of 10.06x suggests undervaluation, as it implies the market expects EPS to more than double to $12.05. The PS ratio of 1.02x is near the low end of its historical range, and the PB ratio of 1.20x is modest. The market is pricing in a successful earnings recovery; if that materializes, the stock is undervalued, but if earnings disappoint, the trailing multiple could compress significantly.
UNM presents a mixed risk/reward profile. The forward PE of 10.06x suggests undervaluation if the company meets its $12.05 EPS estimate, and the 2.29% dividend yield plus aggressive buybacks provide shareholder returns. However, the average analyst target of $101.85 implies only 7.0% upside, and the stock trades near its 52-week high of $96.77, limiting near-term gains. The biggest downside risk is a repeat of the Q3 2025 earnings collapse, which could send the stock toward $88 or lower. For value-oriented investors with a medium-term horizon, UNM is a reasonable buy on dips, but it is not a compelling buy at current levels given the limited upside and high earnings volatility.
UNM is more suitable for long-term investment, given its low beta of 0.264, stable dividend yield of 2.29%, and consistent buyback program. The stock's earnings volatility makes short-term trading risky, as quarterly results can cause sharp price swings. For long-term investors, the forward PE of 10.06x and the potential for EPS growth to $12.05 offer attractive total return prospects. A minimum holding period of 2-3 years is recommended to ride out earnings cycles and benefit from compounding through dividends and buybacks. Short-term traders should focus on technical levels, with support at $85 and resistance at $96.77.